RxDoctor Payments Data

Satyan Sreenath, MD

Otolaryngology · Indianapolis, INNPI 1447638101

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $80,388 of the $103,291 with a category attached, or 77.8%. Stryker accounts for 83.8% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $55,116, more than ten times the $796 reported in 2021. Among otolaryngology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$103,291in general payments, 2019–2025

Across 136 payments — averaging $759.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$87K
  • Optinose US, Inc.$8K
  • 3-d Matrix, Inc.$5K
  • Acclarent, Inc$2K
  • Medtronic$469
  • Integra Lifesciences Corporation$316
  • plus $592 from 5 others

What the payments were for

  • Consulting fees$80,38878%
  • Speaking & faculty fees$8,3508%
  • Travel & lodging$7,5207%
  • Food & beverage$7,0337%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$103,291 in reported general payments places this provider in the 95th percentile of 193 otolaryngology providers in Indiana.

See all otolaryngology providers in Indiana

Medicare billing

Part B allowed, 2024
$73,189
Medicare patients
126
Services billed
426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab15$56,478
XhanceFluticasone Propionate19$11,746
Ipratropium Bromide95$2,429
Azelastine Hcl27$550
Fluticasone Propionate32$359
Omeprazole26$204
Doxycycline Hyclate20$190
Methylprednisolone17$149
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$8,486$11,74619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 193 otolaryngology providers in Indiana.

Other otolaryngology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →